Smith & Nephew - SNN Stock Forecast, Price & News

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Wall Street Analysts Forecast Growth

Several research firms have commented on SNN. Canaccord Genuity Group cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Thursday, July 28th. UBS Group lifted their price objective on shares of Smith & Nephew from GBX 1,200 ($14.50) to GBX 1,295 ($15.65) in a research note on Friday, April 29th. Canaccord Genuity Group cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Thursday, July 28th. Barclays lowered their price objective on shares of Smith & Nephew from GBX 1,650 ($19.94) to GBX 1,630 ($19.70) in a research note on Tuesday, July 5th. Finally, StockNews.com cut shares of Smith & Nephew from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 8th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $1,455.67.

Smith & Nephew Stock Down 0.3 %

Shares of SNN opened at $26.18 on Tuesday. Smith & Nephew has a one year low of $24.80 and a one year high of $39.19. The company has a 50-day moving average of $27.77 and a two-hundred day moving average of $30.87. The company has a current ratio of 1.78, a quick ratio of 0.84 and a debt-to-equity ratio of 0.42.

Smith & Nephew Announces Dividend

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, October 26th. Shareholders of record on Friday, September 30th will be issued a $0.288 dividend. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Thursday, September 29th.